NOVARTIS (NVS)

Karen L. Hale is the Chief Legal and Compliance Officer of Novartis since April 2025 " , previously serving as Chief Legal Officer from May 2021 to April 2025 " " " and as a Board Member of Novartis Pharma AG since 2021. " "

Shreeram Aradhye, M.D. is the President, Development and Chief Medical Officer at Novartis since May 16, 2022; he has held several senior leadership roles at Novartis and previously served as Executive Vice President & Chief Development Officer at Axcella Health and Executive Vice President & Chief Medical Officer at Dicerna Pharmaceuticals. " " "

Steffen Lang, Ph.D. is the President, Operations at Novartis since April 2022, and he previously served as the Global Head of Novartis Technical Operations from 2017 to April 2022. " " "

Victor Bulto is the President, US at Novartis since April 2022 and a member of the Executive Committee since May 2022. " " " Previously, he led key business units at Novartis, including serving as President of Novartis Pharmaceuticals Corporation from 2019 to April 2022. " "

Aharon (Ronny) Gal, Ph.D. has served as the Chief Strategy & Growth Officer at Novartis since July 2022. " " He has an extensive background in biopharmaceutical strategy, analytics, and consulting roles.

Fiona Marshall has served as President of Biomedical Research at Novartis since November 2022. " " " She has extensive experience in neuroscience and biomedical research, previously holding senior roles at Merck & Co., Sosei Heptares, and Heptares Therapeutics. " " "

Harry Kirsch has been serving as the CFO of Novartis since 2013 and has held multiple key financial roles within the company, including positions in the Pharmaceuticals Division. He is scheduled to retire on March 15, 2026. " " "

Klaus Moosmayer served as Chief Ethics, Risk & Compliance Officer at Novartis from 2018 until his departure in March 2025, playing a key role in developing and executing the company’s ethics, risk, and compliance systems while also serving on the Executive Committee. " "

Patrick Horber, M.D. is the President, International at Novartis since December 1, 2023 and a member of the Executive Committee. " " " He has previously held senior leadership roles at AbbVie and Roche. " " "

Ana de Pro Gonzalo has been a Board Member and Independent Non-Executive Director at Novartis since March 4, 2022, leveraging her expertise in finance, capital markets, and technology. " " " Previously, she held executive roles including CFO at Amadeus IT Group and other senior positions at multinational companies. " "

Bridgette Heller has been the Independent Non-Executive Director at NVS since 2020 and serves on the Audit and Compliance, Compensation, and Governance, Sustainability and Nomination Committees. " " " She has held senior leadership roles at companies such as Danone, Merck & Co., and Johnson & Johnson. " " " "

Charles L. Sawyers has served as an Independent Non-Executive Director at Novartis since 2013, and he is widely recognized for his pioneering contributions to cancer research, including the co-development of Gleevec/Glivec. " " " " His extensive career also includes leadership roles at top medical institutions, showcasing his expertise in oncology.

Daniel Hochstrasser has been serving as an Independent Non-Executive Director on the Novartis Board of Directors since March 4, 2022, contributing his extensive dispute resolution and governance expertise. Previously, he held significant legal and leadership roles in his own firm and other organizations. " " "

Elizabeth (Liz) Doherty has served as an Independent Non-Executive Director at Novartis since February 2016. " " Previously, she held senior finance roles at companies such as Unilever, Tesco, and Reckitt Benckiser. " " "

Frans van Houten has been a Board Member at Novartis since 2017 and brings extensive leadership experience from roles such as CEO of Royal Philips NV and CEO of NXP Semiconductors. " "

Joerg Reinhardt has served as Chair of the Board of Directors at Novartis since 2013. " " " " He previously held executive roles at Novartis including Chief Operating Officer (2008-2010) and Head of the Vaccines and Diagnostics Division (2006-2008). " "

John D. Young is a seasoned healthcare professional with over 35 years of industry experience, having held various leadership roles at Pfizer before joining Novartis. He has served as an Independent Non-Executive Director and Board Member at Novartis since March 7, 2023. " "

Nancy C. Andrews has served as an Independent Non-Executive Director at Novartis AG since 2015, participating on both the Risk Committee and the Science & Technology Committee. " " " " She also has extensive experience in medicine and academia, having held leadership roles such as Professor in Residence at Harvard Medical School and Executive Vice President and Chief Scientific Officer at Boston Children’s Hospital. " " "

Patrice Bula has been the Lead Independent Director at Novartis since March 4, 2022 " " and a board member since 2019. " " He brings extensive leadership experience from his previous executive roles at Nestlé, including serving as Executive Vice President and Head of Strategic Business Units from 2011 to 2021. " " " "

Simon Moroney serves as Vice-Chair of the Board of Directors at Novartis since March 4, 2022 and as an Independent Non-Executive Director since 2020. " " " Previously, he co-founded and led MorphoSys AG as CEO from 1992 to 2019. " " " "

Ton Buechner has served as an Independent Non-Executive Director at Novartis since February 2016, where he also chairs the Risk Committee and is a member of the Audit and Compliance Committee. " " " " Previously, he held executive leadership roles such as CEO at Sulzer AG and AkzoNobel NV, contributing significantly to corporate governance and ESG initiatives. " " "

William T. Winters has served as a board member at NVS since 2013 as an Independent Non-Executive Director and sits on key committees including Compensation and Governance, Sustainability and Nomination. " " " "